RSBT-001

**RSBT-001** is a preclinical, inhaled semi-synthetic cannabidiolic acid complex developed as a steroid-free, multi-targeted immune modulator for pulmonary inflammatory disorders. The proprietary product is described as a metal-coordinated micellar cannabinoid complex intended to reduce inflammatory signaling in the lungs and potentially limit inflammation-associated tissue remodeling and fibrosis. RS BioTherapeutics is prioritizing chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, with an IND filing and first-in-human studies targeted for 2026. ([rsbiotherapeutics.com](https://rsbiotherapeutics.com/))